Literature DB >> 19701624

[Internal medical therapy of gastrointestinal stroma tumors].

P Reichardt1.   

Abstract

Until recently no active treatment for advanced or metastatic gastrointestinal stroma tumors (GIST) was available. The tyrosine kinase inhibitor imatinib has revolutionized the treatment of this disease and the median overall survival now reaches 5 years. The standard dose of imatinib is 400 mg per day. Locally advanced GIST should be treated with systemic therapy prior to surgical resection. Imatinib was recently licensed for adjuvant therapy following complete surgical removal of GIST in patients with a significant risk of recurrence.

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19701624     DOI： 10.1007/s00117-009-1854-7

Source DB:  PubMed          Journal:  Radiologe        ISSN： 0033-832X            Impact factor:   0.635


  13 in total

Review 1.  Gastrointestinal stromal tumours: ESMO clinical recommendations for diagnosis, treatment and follow-up.

Authors:  P G Casali; L Jost; P Reichardt; M Schlemmer; J-Y Blay
Journal:  Ann Oncol       Date:  2009-05       Impact factor: 32.976

2.  Trastuzumab-related cardiotoxicity in the herceptin adjuvant trial.

Authors:  Filippo Montemurro; Stefania Redana; Giorgio Valabrega; Rossella Martinello; Massimo Aglietta; Renato Palmiero
Journal:  J Clin Oncol       Date:  2008-04-20       Impact factor: 44.544

3.  Outcome of patients with advanced gastro-intestinal stromal tumours crossing over to a daily imatinib dose of 800 mg after progression on 400 mg.

Authors:  John R Zalcberg; Jaap Verweij; Paolo G Casali; Axel Le Cesne; Peter Reichardt; Jean-Yves Blay; Marcus Schlemmer; Martine Van Glabbeke; Michelle Brown; Ian R Judson
Journal:  Eur J Cancer       Date:  2005-08       Impact factor: 9.162

4.  Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trial.

Authors:  Jaap Verweij; Paolo G Casali; John Zalcberg; Axel LeCesne; Peter Reichardt; Jean-Yves Blay; Rolf Issels; Allan van Oosterom; Pancras C W Hogendoorn; Martine Van Glabbeke; Rossella Bertulli; Ian Judson
Journal:  Lancet       Date:  2004 Sep 25-Oct 1       Impact factor: 79.321

5.  Imatinib plasma levels are correlated with clinical benefit in patients with unresectable/metastatic gastrointestinal stromal tumors.

Authors:  George D Demetri; Yanfeng Wang; Elisabeth Wehrle; Amy Racine; Zariana Nikolova; Charles D Blanke; Heikki Joensuu; Margaret von Mehren
Journal:  J Clin Oncol       Date:  2009-05-18       Impact factor: 44.544

6.  Phase III randomized, intergroup trial assessing imatinib mesylate at two dose levels in patients with unresectable or metastatic gastrointestinal stromal tumors expressing the kit receptor tyrosine kinase: S0033.

Authors:  Charles D Blanke; Cathryn Rankin; George D Demetri; Christopher W Ryan; Margaret von Mehren; Robert S Benjamin; A Kevin Raymond; Vivien H C Bramwell; Laurence H Baker; Robert G Maki; Michael Tanaka; J Randolph Hecht; Michael C Heinrich; Christopher D M Fletcher; John J Crowley; Ernest C Borden
Journal:  J Clin Oncol       Date:  2008-02-01       Impact factor: 44.544

7.  Long-term results from a randomized phase II trial of standard- versus higher-dose imatinib mesylate for patients with unresectable or metastatic gastrointestinal stromal tumors expressing KIT.

Authors:  Charles D Blanke; George D Demetri; Margaret von Mehren; Michael C Heinrich; Burton Eisenberg; Jonathan A Fletcher; Christopher L Corless; Christopher D M Fletcher; Peter J Roberts; Daniela Heinz; Elisabeth Wehre; Zariana Nikolova; Heikki Joensuu
Journal:  J Clin Oncol       Date:  2008-02-01       Impact factor: 44.544

Review 8.  Diagnosis of gastrointestinal stromal tumors: A consensus approach.

Authors:  Christopher D M Fletcher; Jules J Berman; Christopher Corless; Fred Gorstein; Jerzy Lasota; B Jack Longley; Markku Miettinen; Timothy J O'Leary; Helen Remotti; Brian P Rubin; Barry Shmookler; Leslie H Sobin; Sharon W Weiss
Journal:  Hum Pathol       Date:  2002-05       Impact factor: 3.466

9.  Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors.

Authors:  George D Demetri; Margaret von Mehren; Charles D Blanke; Annick D Van den Abbeele; Burton Eisenberg; Peter J Roberts; Michael C Heinrich; David A Tuveson; Samuel Singer; Milos Janicek; Jonathan A Fletcher; Stuart G Silverman; Sandra L Silberman; Renaud Capdeville; Beate Kiese; Bin Peng; Sasa Dimitrijevic; Brian J Druker; Christopher Corless; Christopher D M Fletcher; Heikki Joensuu
Journal:  N Engl J Med       Date:  2002-08-15       Impact factor: 91.245

10.  Adjuvant imatinib mesylate after resection of localised, primary gastrointestinal stromal tumour: a randomised, double-blind, placebo-controlled trial.

Authors:  Ronald P Dematteo; Karla V Ballman; Cristina R Antonescu; Robert G Maki; Peter W T Pisters; George D Demetri; Martin E Blackstein; Charles D Blanke; Margaret von Mehren; Murray F Brennan; Shreyaskumar Patel; Martin D McCarter; Jonathan A Polikoff; Benjamin R Tan; Kouros Owzar
Journal:  Lancet       Date:  2009-03-18       Impact factor: 79.321
View more
  1 in total

1.  Gastrointestinal stromal tumor of the pancreas: A case report and review of the literature.

Authors:  Amel Trabelsi; Lilia Ben Yacoub-Abid; Abdallah Mtimet; Soumaya Ben Abdelkrim; Faten Hammedi; Ali Ben Ali; Moncef Mokni
Journal:  N Am J Med Sci       Date:  2009-11
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.